Vikram Purohit
Stock Analyst at Morgan Stanley
(1.71)
# 3,367
Out of 5,042 analysts
159
Total ratings
30.16%
Success rate
-9.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $31.25 | +8.80% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $65.17 | +21.22% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $4.28 | +37.62% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.52 | -9.42% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $201.60 | +24.01% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $93.48 | -30.47% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $134.99 | +40.75% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.41 | +104.08% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $28.61 | +8.35% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $102.42 | -84.38% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.32 | +374.68% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $25.31 | -60.49% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $8.53 | -29.66% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $12.77 | +228.90% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $61.84 | -33.70% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $17.64 | +126.76% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $3.06 | +324.84% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $21.04 | +80.61% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.63 | +71.97% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.67 | -31.83% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.94 | +1,034.02% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $14.64 | +36.61% | 2 | Aug 5, 2020 |
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $31.25
Upside: +8.80%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $65.17
Upside: +21.22%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $4.28
Upside: +37.62%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.52
Upside: -9.42%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $201.60
Upside: +24.01%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $93.48
Upside: -30.47%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $134.99
Upside: +40.75%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.41
Upside: +104.08%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $28.61
Upside: +8.35%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $102.42
Upside: -84.38%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $6.32
Upside: +374.68%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $25.31
Upside: -60.49%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $8.53
Upside: -29.66%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $12.77
Upside: +228.90%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $61.84
Upside: -33.70%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $17.64
Upside: +126.76%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $3.06
Upside: +324.84%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $21.04
Upside: +80.61%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.63
Upside: +71.97%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.67
Upside: -31.83%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.94
Upside: +1,034.02%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $14.64
Upside: +36.61%